EMA has issued recommendations for the influenza virus strains (see notes further below) that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2026.

Manufacturers of live-attenuated vaccines or egg-based vaccines should include these three virus strains for the 2026/2027 season:

• an A/Missouri/11/2025 (H1N1)pdm09-like virus;

• an A/Darwin/1454/2025 (H3N2)-like virus;

• a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.

Manufacturers of cell-based vaccines should include these three virus strains for the 2026/2027 season:

• an A/Missouri/11/2025 (H1N1)pdm09-like virus;

• an A/Darwin/1415/2025 (H3N2)-like virus;

• a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.

The Agency recommends that marketing authorisation holders submit applications to change the composition of centrally authorised seasonal influenza vaccines by 15 June 2026.